User login
With the emergence of pirfenidone and nintedanib over the past decade or so, pulmonologists now have at their disposal two breakthrough antifibrotic agents for the treatment of idiopathic pulmonary fibrosis.
But these two drugs have a number of shortcomings that a host of investigative agents are aiming to address. For one, while pirfenidone and nintedanib have been shown to slow disease progression and improve symptoms, they don’t stop or reverse the disease. Also, a large number of patients with IPF don’t tolerate these drugs well. And, their high cost is a barrier for many patients.
in terms of therapies or interventions that have better efficacy, better long-term tolerability, and that improve symptoms and quality of life for our patients with IPF disease,” said Joyce Lee, MD, associate professor of medicine–pulmonary at the University of Colorado at Denver, Aurora, and senior medical adviser for research and health care quality for the Pulmonary Fibrosis Foundation.
The National Institutes of Health estimates that more than 30,000 new cases of IPF are diagnosed in the United States annually, and as many as 3 million people have the disease worldwide. The 5-year survival rate is less than 40% after diagnosis. Bloomberg News reported that more than 80 pharmaceutical companies are working on IPF treatments. iHealthcareAnalyst estimates the global market for IPF will reach $10.1 billion by 2029 thanks to rapidly increasing prevalence and incidence with age, premium-priced drugs, and rapid approval of new treatments.
The perils of phase 3 studies
A search on ClinicalTrials.gov turned up 89 investigative IPF treatments in human trials. However, the search for alternatives can be perilous. “In the field, we have gotten used to promising phase 2 studies that failed in the phase 3 stage of development,” Dr. Lee said. “I don’t hold my breath these days just in terms of trying to predict whether or not the efficacy will be present in the phase 3 clinical trial.”
Three notable phase 3 flops include the ISABELA 1 and 2 trials of the autotaxin inhibitor ziritaxestat, which failed to meet their primary endpoint and were halted early (JAMA. 2023;329:1567-78). The phase 3 ZEPHYRUS-1 trial failed to show any benefit of pamrevlumab to improve percent predicted force vital capacity (ppFVC) at week 48, causing discontinuation of a second phase 3 trial. The phase 3 STARSCAPE-OLE study of intravenous recombinant human pentraxin-2 was terminated earlier this year when the sponsor, Hoffmann-LaRoche, decided it was unable to meet its primary objective (NCT04594707).
In the meantime, these six other phase 3 programs in IPF are still in the field:
Anlotinib. A phase 2 and 3 trial in China is evaluating 1-year outcomes of once-daily oral anlotinib for treatment of IPF/progressive fibrosis-interstitial lung disease (PF-ILDS) (NCT05828953). Anlotinib is a tyrosine kinase inhibitor (TKI) that targets four factors: vascular endothelial growth factor receptor (VEGR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. It’s approved in China as a third-line therapy for non–small cell lung cancer (NSCLC).
BI 101550. Enrollment in the FIBRONEER-IPF trial commenced last fall (NCT05321069), with completion scheduled for late next year. BI 1015550 is an oral phosphodiesterase 4B (PDE4B) inhibitor. FIBRONEER-ILD is a separate phase 3 trial in fibrosing idiopathic lung disease (NCT05321082). In both trials, the primary endpoint is the absolute change from baseline in FVC at week 52.
BMS-986278. Results of a phase 2 trial showed that twice-daily treatment with oral BMS-986278 60 mg over 26 weeks reduced the rate of decline in ppFVC by 69% vs. placebo. The phase 3 ALOFT trial has been approved but hasn’t yet started recruiting patients (NCT06003426). BMS-986278 is a lysophosphatidic acid receptor 1 (LPA1) antagonist.
Lanxoprazole. Commonly used to treat and prevent gastrointestinal problems like stomach ulcers and esophagitis, this oral proton pump inhibitor (PPI) is the focus of a trial in the United Kingdom evaluating if PPIs can slow the progression of IPF (NCT04965298).
N-acetylcysteine (NAC). The PRECISIONS trial is evaluating the effect of NAC plus standard-of-care treatment in IPF patients who have the TOLLIP rs3750910 TT genotype (NCT04300920). Participants receive 600 mg NAC orally or matched placebo three times daily for 24 months. Trial completion is scheduled for 2025.
Treprostinil. Already approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, inhaled Treprostinil is the subject of the TETON 1 and 2 trials evaluating its impact on ppFVC after 52 weeks of treatment (NCT04708782, NCT05255991).
Phase 2 candidates
The primary endpoint in most of the phase 2 trials is change in ppFVC capacity from baseline to week 24. The following investigative therapies are in phase 2 trials:
Bexotegrast (PLN-74809), an oral, small molecule, dual-selective inhibitor of alphav/beta6 and alphav/beta1 (NCT04396756).
BBT-877, described as a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as much as 90 percent (NCT05483907).
CC-90001, an oral, once-daily c-Jun N-terminal kinases (JNK) inhibitor. JNKs have been implicated in the underlying mechanisms of fibrosis, including epithelial cell death, inflammation and polarization of profibrotic macrophages, fibroblast activation, and collagen production (NCT03142191).
C21 targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system. It also has an upstream effect by promoting alveolar repair by which it can reduce fibrosis formation, stabilize disease, and increase lung capacity (NCT04533022).
CSL312 (garadacimab) is a humanized anti-FXIIa monoclonal antibody administrated intravenously (NCT05130970).
Cudetaxestat, a noncompetitive autotaxin inhibitor (NCT05373914).
Bersiposocin/DWN12088, an inhibitor of prolyl-tRNA synthetase 1 (PARS1), which is suspected to control the pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases (NCT05389215).
ENV-101, a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a key role in IPF. This agent was originally developed to target Hh-driven cancers (NCT04968574).
GKT137831 (setanaxib) inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. (NCT03865927).
HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist. (NCT05032066)
Ifetroban, a potent and selective thromboxane-prostanoid receptor (TPr) antagonist, which exhibits a high affinity for TPr on platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity (NCT05571059).
INS018_055, a small-molecule, oral antifibrotic candidate notable for being the first entirely AI-generated drug to enter phase 2 trials. Trial enrollment started in October (NCT05975983, NCT05983920)
Jaktinib dihydrochloride monohydrate, an oral JAK1, JAK2, and JAK3 inhibitor (NCT04312594).
Leramistat, an anti–tumor necrosis factor (TNF) agent (NCT05951296).
LTP001, an oral, selectively deuterated form of pirfenidone designed to retain the antifibrotic and anti-inflammatory activity of pirfenidone with a differentiated pharmacokinetic profile (NCT05497284, NCT05321420).
ME-015 (suplatast tosilate) aims to stabilize ion channels in the neuronal endings in the lungs that mediate IPF-related cough (NCT05983471).
Nalbuphine, a small-molecule, dual-mechanism treatment for chronic cough in IPF. It acts as both a mu opioid receptor antagonist and a kappa opioid receptor agonist (NCT05964335). The CANAL trial, complete last year, is evaluating an extended-release formulation (NCT04030026).
NP-120 (ifenprodil), a small-molecule N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA-type subunit 2B (GluN2B) (NCT04318704).
Orvepitant, a selective antagonist for the NK₁ receptor, is being evaluated to treat IPF-related cough (NCT05815089).
RXC007 (zelasudil), a Rho-associated coiled-coil–containing protein kinase 2 (ROCK2) selective inhibitor, was granted FDA orphan drug designation in August 2023 (NCT05570058).
Saracatinib, a selective Src kinase inhibitor originally developed for oncological indications (NCT04598919).
SHR-1906, an intravenous treatment, inhibits binding of a target protein to a variety of cytokines and growth factors, affects downstream signaling pathways, and reduces cell proliferation and migration (NCT05722964).
TTI-101, an oral, small-molecule inhibitor of signal transducer and activator of transcription (STAT3), which has been found to accumulate in the lungs of IPF patients (NCT05671835).
VAY736 (lanalumab), a BAFF-R inhibitor (NCT03287414).
Vixarelimab, a human monoclonal oncastatin M receptor beta antibody (NCT05785624).
Some investigative programs, however, didn’t make it out of phase 2. The trial evaluating inhaled GB0139, a selective functional antagonist of G-protein–coupled receptor 84, which plays a key role in fibrosis, failed to meet its primary endpoint (NCT03832946). Likewise, oral GLPG1205 failed to show a significant difference in FVC decline vs. placebo (NCT03725852). The program to develop SAR156597, also known as romilkimab, was halted (NCT02345070). ND-L02-s0201n, an siRNA oligonucleotide drug designed to inhibit heat shock protein 47 (HSP47), which regulates collagen synthesis and secretion that causes fibrosis, didn’t show the expected efficacy (NCT03538301).
Phase 1 trials
No fewer than 27 phase 1 trials are evaluating investigative treatments for IPF, many in the early phase or not yet recruiting. According to GlobalData, phase 1 drugs for IPF have a 66% chance of moving onto phase 2. Among the advanced phase 1 trials that have gained corporate backing are:
9MW3811, an anti–interleukin-11 monoclonal antibody IV injection (NCT05912049).
ANG-3070, an oral tyrosine kinase inhibitor targeting platelet-derived growth factor (PDGFR) alpha and beta (NCT05387785).
C106, an angiotensin II type 2 receptor agonist (NCT05427253).
HuL001, which targets alpha-enolase (NCT04540770).
LTI-03, a Caveolin-1 (Cav1)-related peptide designed to restore Cav1 expression in lung tissue (NCT05954988).
ORIN1001, a first-in-class small molecule that selectively blocks the inositol requiring enzyme 1alphase (IRE1) RNAse and blocks X-box binding protein 1 (XBP1) activation (NCT04643769).
PRS-220 is an orally inhaled anticalin protein targeting connective tissue growth factor (CTGF) (NTC05473533).
TRK-250, a single-strand, long-chain nucleic acid that selectively suppresses expression of transforming growth factor-beta 1 (TGF-beta1) protein (NCT03727802).
“While we have therapies that we’re able to give patients, we need to do more and we need to do better,” Dr. Lee said. “We’re all hopeful the next phase 3 clinical trial will be something that will help change the treatment paradigm for our patients. We’re very patient, and hopefully those that are interested in improving this treatment landscape will continue to persist.”
Dr. Lee disclosed financial relationships with Boehringer Ingelheim, Pliant Therapeutics, Blade Therapeutics, United Therapeutics, Eleven P15. and Avalyn Pharma.
With the emergence of pirfenidone and nintedanib over the past decade or so, pulmonologists now have at their disposal two breakthrough antifibrotic agents for the treatment of idiopathic pulmonary fibrosis.
But these two drugs have a number of shortcomings that a host of investigative agents are aiming to address. For one, while pirfenidone and nintedanib have been shown to slow disease progression and improve symptoms, they don’t stop or reverse the disease. Also, a large number of patients with IPF don’t tolerate these drugs well. And, their high cost is a barrier for many patients.
in terms of therapies or interventions that have better efficacy, better long-term tolerability, and that improve symptoms and quality of life for our patients with IPF disease,” said Joyce Lee, MD, associate professor of medicine–pulmonary at the University of Colorado at Denver, Aurora, and senior medical adviser for research and health care quality for the Pulmonary Fibrosis Foundation.
The National Institutes of Health estimates that more than 30,000 new cases of IPF are diagnosed in the United States annually, and as many as 3 million people have the disease worldwide. The 5-year survival rate is less than 40% after diagnosis. Bloomberg News reported that more than 80 pharmaceutical companies are working on IPF treatments. iHealthcareAnalyst estimates the global market for IPF will reach $10.1 billion by 2029 thanks to rapidly increasing prevalence and incidence with age, premium-priced drugs, and rapid approval of new treatments.
The perils of phase 3 studies
A search on ClinicalTrials.gov turned up 89 investigative IPF treatments in human trials. However, the search for alternatives can be perilous. “In the field, we have gotten used to promising phase 2 studies that failed in the phase 3 stage of development,” Dr. Lee said. “I don’t hold my breath these days just in terms of trying to predict whether or not the efficacy will be present in the phase 3 clinical trial.”
Three notable phase 3 flops include the ISABELA 1 and 2 trials of the autotaxin inhibitor ziritaxestat, which failed to meet their primary endpoint and were halted early (JAMA. 2023;329:1567-78). The phase 3 ZEPHYRUS-1 trial failed to show any benefit of pamrevlumab to improve percent predicted force vital capacity (ppFVC) at week 48, causing discontinuation of a second phase 3 trial. The phase 3 STARSCAPE-OLE study of intravenous recombinant human pentraxin-2 was terminated earlier this year when the sponsor, Hoffmann-LaRoche, decided it was unable to meet its primary objective (NCT04594707).
In the meantime, these six other phase 3 programs in IPF are still in the field:
Anlotinib. A phase 2 and 3 trial in China is evaluating 1-year outcomes of once-daily oral anlotinib for treatment of IPF/progressive fibrosis-interstitial lung disease (PF-ILDS) (NCT05828953). Anlotinib is a tyrosine kinase inhibitor (TKI) that targets four factors: vascular endothelial growth factor receptor (VEGR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. It’s approved in China as a third-line therapy for non–small cell lung cancer (NSCLC).
BI 101550. Enrollment in the FIBRONEER-IPF trial commenced last fall (NCT05321069), with completion scheduled for late next year. BI 1015550 is an oral phosphodiesterase 4B (PDE4B) inhibitor. FIBRONEER-ILD is a separate phase 3 trial in fibrosing idiopathic lung disease (NCT05321082). In both trials, the primary endpoint is the absolute change from baseline in FVC at week 52.
BMS-986278. Results of a phase 2 trial showed that twice-daily treatment with oral BMS-986278 60 mg over 26 weeks reduced the rate of decline in ppFVC by 69% vs. placebo. The phase 3 ALOFT trial has been approved but hasn’t yet started recruiting patients (NCT06003426). BMS-986278 is a lysophosphatidic acid receptor 1 (LPA1) antagonist.
Lanxoprazole. Commonly used to treat and prevent gastrointestinal problems like stomach ulcers and esophagitis, this oral proton pump inhibitor (PPI) is the focus of a trial in the United Kingdom evaluating if PPIs can slow the progression of IPF (NCT04965298).
N-acetylcysteine (NAC). The PRECISIONS trial is evaluating the effect of NAC plus standard-of-care treatment in IPF patients who have the TOLLIP rs3750910 TT genotype (NCT04300920). Participants receive 600 mg NAC orally or matched placebo three times daily for 24 months. Trial completion is scheduled for 2025.
Treprostinil. Already approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, inhaled Treprostinil is the subject of the TETON 1 and 2 trials evaluating its impact on ppFVC after 52 weeks of treatment (NCT04708782, NCT05255991).
Phase 2 candidates
The primary endpoint in most of the phase 2 trials is change in ppFVC capacity from baseline to week 24. The following investigative therapies are in phase 2 trials:
Bexotegrast (PLN-74809), an oral, small molecule, dual-selective inhibitor of alphav/beta6 and alphav/beta1 (NCT04396756).
BBT-877, described as a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as much as 90 percent (NCT05483907).
CC-90001, an oral, once-daily c-Jun N-terminal kinases (JNK) inhibitor. JNKs have been implicated in the underlying mechanisms of fibrosis, including epithelial cell death, inflammation and polarization of profibrotic macrophages, fibroblast activation, and collagen production (NCT03142191).
C21 targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system. It also has an upstream effect by promoting alveolar repair by which it can reduce fibrosis formation, stabilize disease, and increase lung capacity (NCT04533022).
CSL312 (garadacimab) is a humanized anti-FXIIa monoclonal antibody administrated intravenously (NCT05130970).
Cudetaxestat, a noncompetitive autotaxin inhibitor (NCT05373914).
Bersiposocin/DWN12088, an inhibitor of prolyl-tRNA synthetase 1 (PARS1), which is suspected to control the pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases (NCT05389215).
ENV-101, a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a key role in IPF. This agent was originally developed to target Hh-driven cancers (NCT04968574).
GKT137831 (setanaxib) inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. (NCT03865927).
HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist. (NCT05032066)
Ifetroban, a potent and selective thromboxane-prostanoid receptor (TPr) antagonist, which exhibits a high affinity for TPr on platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity (NCT05571059).
INS018_055, a small-molecule, oral antifibrotic candidate notable for being the first entirely AI-generated drug to enter phase 2 trials. Trial enrollment started in October (NCT05975983, NCT05983920)
Jaktinib dihydrochloride monohydrate, an oral JAK1, JAK2, and JAK3 inhibitor (NCT04312594).
Leramistat, an anti–tumor necrosis factor (TNF) agent (NCT05951296).
LTP001, an oral, selectively deuterated form of pirfenidone designed to retain the antifibrotic and anti-inflammatory activity of pirfenidone with a differentiated pharmacokinetic profile (NCT05497284, NCT05321420).
ME-015 (suplatast tosilate) aims to stabilize ion channels in the neuronal endings in the lungs that mediate IPF-related cough (NCT05983471).
Nalbuphine, a small-molecule, dual-mechanism treatment for chronic cough in IPF. It acts as both a mu opioid receptor antagonist and a kappa opioid receptor agonist (NCT05964335). The CANAL trial, complete last year, is evaluating an extended-release formulation (NCT04030026).
NP-120 (ifenprodil), a small-molecule N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA-type subunit 2B (GluN2B) (NCT04318704).
Orvepitant, a selective antagonist for the NK₁ receptor, is being evaluated to treat IPF-related cough (NCT05815089).
RXC007 (zelasudil), a Rho-associated coiled-coil–containing protein kinase 2 (ROCK2) selective inhibitor, was granted FDA orphan drug designation in August 2023 (NCT05570058).
Saracatinib, a selective Src kinase inhibitor originally developed for oncological indications (NCT04598919).
SHR-1906, an intravenous treatment, inhibits binding of a target protein to a variety of cytokines and growth factors, affects downstream signaling pathways, and reduces cell proliferation and migration (NCT05722964).
TTI-101, an oral, small-molecule inhibitor of signal transducer and activator of transcription (STAT3), which has been found to accumulate in the lungs of IPF patients (NCT05671835).
VAY736 (lanalumab), a BAFF-R inhibitor (NCT03287414).
Vixarelimab, a human monoclonal oncastatin M receptor beta antibody (NCT05785624).
Some investigative programs, however, didn’t make it out of phase 2. The trial evaluating inhaled GB0139, a selective functional antagonist of G-protein–coupled receptor 84, which plays a key role in fibrosis, failed to meet its primary endpoint (NCT03832946). Likewise, oral GLPG1205 failed to show a significant difference in FVC decline vs. placebo (NCT03725852). The program to develop SAR156597, also known as romilkimab, was halted (NCT02345070). ND-L02-s0201n, an siRNA oligonucleotide drug designed to inhibit heat shock protein 47 (HSP47), which regulates collagen synthesis and secretion that causes fibrosis, didn’t show the expected efficacy (NCT03538301).
Phase 1 trials
No fewer than 27 phase 1 trials are evaluating investigative treatments for IPF, many in the early phase or not yet recruiting. According to GlobalData, phase 1 drugs for IPF have a 66% chance of moving onto phase 2. Among the advanced phase 1 trials that have gained corporate backing are:
9MW3811, an anti–interleukin-11 monoclonal antibody IV injection (NCT05912049).
ANG-3070, an oral tyrosine kinase inhibitor targeting platelet-derived growth factor (PDGFR) alpha and beta (NCT05387785).
C106, an angiotensin II type 2 receptor agonist (NCT05427253).
HuL001, which targets alpha-enolase (NCT04540770).
LTI-03, a Caveolin-1 (Cav1)-related peptide designed to restore Cav1 expression in lung tissue (NCT05954988).
ORIN1001, a first-in-class small molecule that selectively blocks the inositol requiring enzyme 1alphase (IRE1) RNAse and blocks X-box binding protein 1 (XBP1) activation (NCT04643769).
PRS-220 is an orally inhaled anticalin protein targeting connective tissue growth factor (CTGF) (NTC05473533).
TRK-250, a single-strand, long-chain nucleic acid that selectively suppresses expression of transforming growth factor-beta 1 (TGF-beta1) protein (NCT03727802).
“While we have therapies that we’re able to give patients, we need to do more and we need to do better,” Dr. Lee said. “We’re all hopeful the next phase 3 clinical trial will be something that will help change the treatment paradigm for our patients. We’re very patient, and hopefully those that are interested in improving this treatment landscape will continue to persist.”
Dr. Lee disclosed financial relationships with Boehringer Ingelheim, Pliant Therapeutics, Blade Therapeutics, United Therapeutics, Eleven P15. and Avalyn Pharma.
With the emergence of pirfenidone and nintedanib over the past decade or so, pulmonologists now have at their disposal two breakthrough antifibrotic agents for the treatment of idiopathic pulmonary fibrosis.
But these two drugs have a number of shortcomings that a host of investigative agents are aiming to address. For one, while pirfenidone and nintedanib have been shown to slow disease progression and improve symptoms, they don’t stop or reverse the disease. Also, a large number of patients with IPF don’t tolerate these drugs well. And, their high cost is a barrier for many patients.
in terms of therapies or interventions that have better efficacy, better long-term tolerability, and that improve symptoms and quality of life for our patients with IPF disease,” said Joyce Lee, MD, associate professor of medicine–pulmonary at the University of Colorado at Denver, Aurora, and senior medical adviser for research and health care quality for the Pulmonary Fibrosis Foundation.
The National Institutes of Health estimates that more than 30,000 new cases of IPF are diagnosed in the United States annually, and as many as 3 million people have the disease worldwide. The 5-year survival rate is less than 40% after diagnosis. Bloomberg News reported that more than 80 pharmaceutical companies are working on IPF treatments. iHealthcareAnalyst estimates the global market for IPF will reach $10.1 billion by 2029 thanks to rapidly increasing prevalence and incidence with age, premium-priced drugs, and rapid approval of new treatments.
The perils of phase 3 studies
A search on ClinicalTrials.gov turned up 89 investigative IPF treatments in human trials. However, the search for alternatives can be perilous. “In the field, we have gotten used to promising phase 2 studies that failed in the phase 3 stage of development,” Dr. Lee said. “I don’t hold my breath these days just in terms of trying to predict whether or not the efficacy will be present in the phase 3 clinical trial.”
Three notable phase 3 flops include the ISABELA 1 and 2 trials of the autotaxin inhibitor ziritaxestat, which failed to meet their primary endpoint and were halted early (JAMA. 2023;329:1567-78). The phase 3 ZEPHYRUS-1 trial failed to show any benefit of pamrevlumab to improve percent predicted force vital capacity (ppFVC) at week 48, causing discontinuation of a second phase 3 trial. The phase 3 STARSCAPE-OLE study of intravenous recombinant human pentraxin-2 was terminated earlier this year when the sponsor, Hoffmann-LaRoche, decided it was unable to meet its primary objective (NCT04594707).
In the meantime, these six other phase 3 programs in IPF are still in the field:
Anlotinib. A phase 2 and 3 trial in China is evaluating 1-year outcomes of once-daily oral anlotinib for treatment of IPF/progressive fibrosis-interstitial lung disease (PF-ILDS) (NCT05828953). Anlotinib is a tyrosine kinase inhibitor (TKI) that targets four factors: vascular endothelial growth factor receptor (VEGR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. It’s approved in China as a third-line therapy for non–small cell lung cancer (NSCLC).
BI 101550. Enrollment in the FIBRONEER-IPF trial commenced last fall (NCT05321069), with completion scheduled for late next year. BI 1015550 is an oral phosphodiesterase 4B (PDE4B) inhibitor. FIBRONEER-ILD is a separate phase 3 trial in fibrosing idiopathic lung disease (NCT05321082). In both trials, the primary endpoint is the absolute change from baseline in FVC at week 52.
BMS-986278. Results of a phase 2 trial showed that twice-daily treatment with oral BMS-986278 60 mg over 26 weeks reduced the rate of decline in ppFVC by 69% vs. placebo. The phase 3 ALOFT trial has been approved but hasn’t yet started recruiting patients (NCT06003426). BMS-986278 is a lysophosphatidic acid receptor 1 (LPA1) antagonist.
Lanxoprazole. Commonly used to treat and prevent gastrointestinal problems like stomach ulcers and esophagitis, this oral proton pump inhibitor (PPI) is the focus of a trial in the United Kingdom evaluating if PPIs can slow the progression of IPF (NCT04965298).
N-acetylcysteine (NAC). The PRECISIONS trial is evaluating the effect of NAC plus standard-of-care treatment in IPF patients who have the TOLLIP rs3750910 TT genotype (NCT04300920). Participants receive 600 mg NAC orally or matched placebo three times daily for 24 months. Trial completion is scheduled for 2025.
Treprostinil. Already approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, inhaled Treprostinil is the subject of the TETON 1 and 2 trials evaluating its impact on ppFVC after 52 weeks of treatment (NCT04708782, NCT05255991).
Phase 2 candidates
The primary endpoint in most of the phase 2 trials is change in ppFVC capacity from baseline to week 24. The following investigative therapies are in phase 2 trials:
Bexotegrast (PLN-74809), an oral, small molecule, dual-selective inhibitor of alphav/beta6 and alphav/beta1 (NCT04396756).
BBT-877, described as a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as much as 90 percent (NCT05483907).
CC-90001, an oral, once-daily c-Jun N-terminal kinases (JNK) inhibitor. JNKs have been implicated in the underlying mechanisms of fibrosis, including epithelial cell death, inflammation and polarization of profibrotic macrophages, fibroblast activation, and collagen production (NCT03142191).
C21 targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system. It also has an upstream effect by promoting alveolar repair by which it can reduce fibrosis formation, stabilize disease, and increase lung capacity (NCT04533022).
CSL312 (garadacimab) is a humanized anti-FXIIa monoclonal antibody administrated intravenously (NCT05130970).
Cudetaxestat, a noncompetitive autotaxin inhibitor (NCT05373914).
Bersiposocin/DWN12088, an inhibitor of prolyl-tRNA synthetase 1 (PARS1), which is suspected to control the pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases (NCT05389215).
ENV-101, a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a key role in IPF. This agent was originally developed to target Hh-driven cancers (NCT04968574).
GKT137831 (setanaxib) inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. (NCT03865927).
HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist. (NCT05032066)
Ifetroban, a potent and selective thromboxane-prostanoid receptor (TPr) antagonist, which exhibits a high affinity for TPr on platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity (NCT05571059).
INS018_055, a small-molecule, oral antifibrotic candidate notable for being the first entirely AI-generated drug to enter phase 2 trials. Trial enrollment started in October (NCT05975983, NCT05983920)
Jaktinib dihydrochloride monohydrate, an oral JAK1, JAK2, and JAK3 inhibitor (NCT04312594).
Leramistat, an anti–tumor necrosis factor (TNF) agent (NCT05951296).
LTP001, an oral, selectively deuterated form of pirfenidone designed to retain the antifibrotic and anti-inflammatory activity of pirfenidone with a differentiated pharmacokinetic profile (NCT05497284, NCT05321420).
ME-015 (suplatast tosilate) aims to stabilize ion channels in the neuronal endings in the lungs that mediate IPF-related cough (NCT05983471).
Nalbuphine, a small-molecule, dual-mechanism treatment for chronic cough in IPF. It acts as both a mu opioid receptor antagonist and a kappa opioid receptor agonist (NCT05964335). The CANAL trial, complete last year, is evaluating an extended-release formulation (NCT04030026).
NP-120 (ifenprodil), a small-molecule N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA-type subunit 2B (GluN2B) (NCT04318704).
Orvepitant, a selective antagonist for the NK₁ receptor, is being evaluated to treat IPF-related cough (NCT05815089).
RXC007 (zelasudil), a Rho-associated coiled-coil–containing protein kinase 2 (ROCK2) selective inhibitor, was granted FDA orphan drug designation in August 2023 (NCT05570058).
Saracatinib, a selective Src kinase inhibitor originally developed for oncological indications (NCT04598919).
SHR-1906, an intravenous treatment, inhibits binding of a target protein to a variety of cytokines and growth factors, affects downstream signaling pathways, and reduces cell proliferation and migration (NCT05722964).
TTI-101, an oral, small-molecule inhibitor of signal transducer and activator of transcription (STAT3), which has been found to accumulate in the lungs of IPF patients (NCT05671835).
VAY736 (lanalumab), a BAFF-R inhibitor (NCT03287414).
Vixarelimab, a human monoclonal oncastatin M receptor beta antibody (NCT05785624).
Some investigative programs, however, didn’t make it out of phase 2. The trial evaluating inhaled GB0139, a selective functional antagonist of G-protein–coupled receptor 84, which plays a key role in fibrosis, failed to meet its primary endpoint (NCT03832946). Likewise, oral GLPG1205 failed to show a significant difference in FVC decline vs. placebo (NCT03725852). The program to develop SAR156597, also known as romilkimab, was halted (NCT02345070). ND-L02-s0201n, an siRNA oligonucleotide drug designed to inhibit heat shock protein 47 (HSP47), which regulates collagen synthesis and secretion that causes fibrosis, didn’t show the expected efficacy (NCT03538301).
Phase 1 trials
No fewer than 27 phase 1 trials are evaluating investigative treatments for IPF, many in the early phase or not yet recruiting. According to GlobalData, phase 1 drugs for IPF have a 66% chance of moving onto phase 2. Among the advanced phase 1 trials that have gained corporate backing are:
9MW3811, an anti–interleukin-11 monoclonal antibody IV injection (NCT05912049).
ANG-3070, an oral tyrosine kinase inhibitor targeting platelet-derived growth factor (PDGFR) alpha and beta (NCT05387785).
C106, an angiotensin II type 2 receptor agonist (NCT05427253).
HuL001, which targets alpha-enolase (NCT04540770).
LTI-03, a Caveolin-1 (Cav1)-related peptide designed to restore Cav1 expression in lung tissue (NCT05954988).
ORIN1001, a first-in-class small molecule that selectively blocks the inositol requiring enzyme 1alphase (IRE1) RNAse and blocks X-box binding protein 1 (XBP1) activation (NCT04643769).
PRS-220 is an orally inhaled anticalin protein targeting connective tissue growth factor (CTGF) (NTC05473533).
TRK-250, a single-strand, long-chain nucleic acid that selectively suppresses expression of transforming growth factor-beta 1 (TGF-beta1) protein (NCT03727802).
“While we have therapies that we’re able to give patients, we need to do more and we need to do better,” Dr. Lee said. “We’re all hopeful the next phase 3 clinical trial will be something that will help change the treatment paradigm for our patients. We’re very patient, and hopefully those that are interested in improving this treatment landscape will continue to persist.”
Dr. Lee disclosed financial relationships with Boehringer Ingelheim, Pliant Therapeutics, Blade Therapeutics, United Therapeutics, Eleven P15. and Avalyn Pharma.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>165360</fileName> <TBEID>0C04C83A.SIG</TBEID> <TBUniqueIdentifier>MD_0C04C83A</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname>IPF_Drug_Pipeline</storyname> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20231010T121501</QCDate> <firstPublished>20231010T123132</firstPublished> <LastPublished>20231010T123132</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20231010T123132</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber>NA</meetingNumber> <byline>Richard Mark Kirkner (rmkirkner@verizon.net)</byline> <bylineText>RICHARD MARK KIRKNER</bylineText> <bylineFull>RICHARD MARK KIRKNER</bylineFull> <bylineTitleText>MDedge News</bylineTitleText> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>“There are no curative therapies that improve lung function or improve symptoms, so there remains a very large unmet need</metaDescription> <articlePDF/> <teaserImage>224380</teaserImage> <teaser>Almost 90 clinical trials are evaluating drugs to that target unmet needs for treating idiopathic pulmonary fibrosis. </teaser> <title>IPF pipeline crowded with new drug candidates</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>chph</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">6</term> </publications> <sections> <term canonical="true">27980</term> <term>39313</term> </sections> <topics> <term canonical="true">284</term> </topics> <links> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/2400a64e.jpg</altRep> <description role="drol:caption"/> <description role="drol:credit">Artfoliophoto/Thinkstock</description> </link> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/240122b1.jpg</altRep> <description role="drol:caption">Dr. Joyce Lee</description> <description role="drol:credit">Joyce Lee, MD</description> </link> </links> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>IPF pipeline crowded with new drug candidates</title> <deck/> </itemMeta> <itemContent> <p>With the emergence of pirfenidone and nintedanib over the past decade or so, pulmonologists now have at their disposal two breakthrough antifibrotic agents for the treatment of idiopathic pulmonary fibrosis. </p> <p>[[{"fid":"224380","view_mode":"medstat_image_flush_right","fields":{"format":"medstat_image_flush_right","field_file_image_alt_text[und][0][value]":"Pills of various kinds and colors","field_file_image_credit[und][0][value]":"Artfoliophoto/Thinkstock","field_file_image_caption[und][0][value]":""},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_right"}}]]But these two drugs have a number of shortcomings that a host of investigative agents are aiming to address. For one, while pirfenidone and nintedanib have been shown to slow disease progression and improve symptoms, they don’t stop or reverse the disease. Also, a large number of patients with IPF don’t tolerate these drugs well. And, their high cost is a barrier for many patients. <br/><br/>[[{"fid":"298467","view_mode":"medstat_image_flush_left","fields":{"format":"medstat_image_flush_left","field_file_image_alt_text[und][0][value]":"Joyce Lee, MD, associate professor of medicine-pulmonary at the University of Colorado at Denver, Aurora, and senior medical adviser for research and healthcare quality for the Pulmonary Fibrosis Foundation","field_file_image_credit[und][0][value]":"Joyce Lee, MD","field_file_image_caption[und][0][value]":"Dr. Joyce Lee"},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_left"}}]]<span class="tag metaDescription">“There are no curative therapies that improve lung function or improve symptoms, so there remains a very large unmet need </span>in terms of therapies or interventions that have better efficacy, better long-term tolerability, and that improve symptoms and quality of life for our patients with IPF disease,” said Joyce Lee, MD, associate professor of medicine–pulmonary at the University of Colorado at Denver, Aurora, and senior medical adviser for research and health care quality for the Pulmonary Fibrosis Foundation. <br/><br/>The National Institutes of Health estimates that more than 30,000 new cases of IPF are diagnosed in the United States annually, and as many as 3 million people have the disease worldwide. The 5-year survival rate is less than 40% after diagnosis. Bloomberg News reported that more than 80 pharmaceutical companies are working on IPF treatments. <a href="https://www.ihealthcareanalyst.com/global-idiopathic-pulmonary-fibrosis-treatment-market/">iHealthcareAnalyst</a> estimates the global market for IPF will reach $10.1 billion by 2029 thanks to rapidly increasing prevalence and incidence with age, premium-priced drugs, and rapid approval of new treatments. <br/><br/></p> <h2>The perils of phase 3 studies</h2> <p>A search on ClinicalTrials.gov turned up 89 investigative IPF treatments in human trials. However, the search for alternatives can be perilous. “In the field, we have gotten used to promising phase 2 studies that failed in the phase 3 stage of development,” Dr. Lee said. “I don’t hold my breath these days just in terms of trying to predict whether or not the efficacy will be present in the phase 3 clinical trial.”</p> <p>Three notable phase 3 flops include the ISABELA 1 and 2 trials of the autotaxin inhibitor ziritaxestat, which failed to meet their primary endpoint and were halted early (<a href="https://jamanetwork.com/journals/jama/fullarticle/2804605">JAMA. 2023;329:1567-78</a>). The phase 3 ZEPHYRUS-1 trial failed to show any benefit of pamrevlumab to improve percent predicted force vital capacity (ppFVC) at week 48, causing discontinuation of a second phase 3 trial. The phase 3 STARSCAPE-OLE study of intravenous recombinant human pentraxin-2 was terminated earlier this year when the sponsor, Hoffmann-LaRoche, decided it was unable to meet its primary objective (<a href="https://clinicaltrials.gov/study/NCT04594707?cond=Idiopathic Pulmonary Fibrosis&page=10&rank=99">NCT04594707</a>). <br/><br/>In the meantime, these six other phase 3 programs in IPF are still in the field:<br/><br/><strong>Anlotinib</strong>. A phase 2 and 3 trial in China is evaluating 1-year outcomes of once-daily oral anlotinib for treatment of IPF/progressive fibrosis-interstitial lung disease (PF-ILDS) (<a href="https://clinicaltrials.gov/study/NCT05828953">NCT05828953</a>). Anlotinib is a tyrosine kinase inhibitor (TKI) that targets four factors: vascular endothelial growth factor receptor (VEGR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. It’s approved in China as a third-line therapy for non–small cell lung cancer (NSCLC). <br/><br/><strong>BI 101550</strong>. Enrollment in the FIBRONEER-IPF trial commenced last fall (<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05321069">NCT05321069</a>), with completion scheduled for late next year. BI 1015550 is an oral phosphodiesterase 4B (PDE4B) inhibitor. FIBRONEER-ILD is a separate phase 3 trial in fibrosing idiopathic lung disease (<a href="https://c212.net/c/link/?t=0&l=en&o=3688793-1&h=65116698&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05321082&a=NCT05321082">NCT05321082</a>). In both trials, the primary endpoint is the absolute change from baseline in FVC at week 52.<br/><br/><strong>BMS-986278</strong>. Results of a phase 2 trial showed that twice-daily treatment with oral BMS-986278 60 mg over 26 weeks reduced the rate of decline in ppFVC by 69% vs. placebo. The phase 3 ALOFT trial has been approved but hasn’t yet started recruiting patients (<a href="https://clinicaltrials.gov/study/NCT06003426">NCT06003426</a>). BMS-986278 is a lysophosphatidic acid receptor 1 (LPA1) antagonist.<br/><br/><strong>Lanxoprazole</strong>. Commonly used to treat and prevent gastrointestinal problems like stomach ulcers and esophagitis, this oral proton pump inhibitor (PPI) is the focus of a trial in the United Kingdom evaluating if PPIs can slow the progression of IPF (<a href="https://clinicaltrials.gov/study/NCT04965298">NCT04965298</a>).<br/><br/><strong>N-acetylcysteine (NAC)</strong>. The PRECISIONS trial is evaluating the effect of NAC plus standard-of-care treatment in IPF patients who have the TOLLIP rs3750910 TT genotype (<a href="https://clinicaltrials.gov/study/NCT04300920">NCT04300920</a>). Participants receive 600 mg NAC orally or matched placebo three times daily for 24 months. Trial completion is scheduled for 2025. <br/><br/><strong>Treprostinil</strong>. Already approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, inhaled Treprostinil is the subject of the TETON 1 and 2 trials evaluating its impact on ppFVC after 52 weeks of treatment (<a href="https://clinicaltrials.gov/study/NCT04708782">NCT04708782</a>, <span class="Hyperlink"><a href="https://clinicaltrials.gov/study/NCT05255991">NCT05255991</a></span>). <br/><br/></p> <h2>Phase 2 candidates</h2> <p>The primary endpoint in most of the phase 2 trials is change in ppFVC capacity from baseline to week 24. The following investigative therapies are in phase 2 trials:</p> <p><strong>Bexotegrast (PLN-74809)</strong>, an oral, small molecule, dual-selective inhibitor of alphav/beta6 and alphav/beta1 (<a href="https://clinicaltrials.gov/study/NCT04396756?cond=Idiopathic Pulmonary Fibrosis&term=INTEGRIS-IPF&rank=1">NCT04396756</a>).<br/><br/><strong>BBT-877</strong>, described as a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as much as 90 percent (<a href="https://clinicaltrials.gov/study/NCT05483907">NCT05483907</a>).<br/><br/><strong>CC-90001</strong>, an oral, once-daily c-Jun N-terminal kinases (JNK) inhibitor. JNKs have been implicated in the underlying mechanisms of fibrosis, including epithelial cell death, inflammation and polarization of profibrotic macrophages, fibroblast activation, and collagen production (<a href="https://bmjopenrespres.bmj.com/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03142191&atom=%2Fbmjresp%2F9%2F1%2Fe001060.atom">NCT03142191</a>).<br/><br/><strong>C21</strong> targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system. It also has an upstream effect by promoting alveolar repair by which it can reduce fibrosis formation, stabilize disease, and increase lung capacity (<a href="https://clinicaltrials.gov/study/NCT04533022">NCT04533022</a>).<br/><br/><strong>CSL312 (garadacimab)</strong> is a humanized anti-FXIIa monoclonal antibody administrated intravenously (<a href="https://clinicaltrials.gov/ct2/show/NCT05130970">NCT05130970</a>).<br/><br/><strong>Cudetaxestat</strong>, a noncompetitive autotaxin inhibitor (<a href="https://clinicaltrials.gov/study/NCT05373914">NCT05373914</a>). <br/><br/><strong>Bersiposocin/DWN12088</strong>, an inhibitor of prolyl-tRNA synthetase 1 (PARS1), which is suspected to control the pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases (<a href="https://clinicaltrials.gov/study/NCT05389215">NCT05389215</a>). <br/><br/><strong>ENV-101</strong>, a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a key role in IPF. This agent was originally developed to target Hh-driven cancers (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04968574&esheet=53546405&newsitemid=20230906375636&lan=en-US&anchor=NCT04968574&index=3&md5=46120e343eb4ff31f31fc7d63e93eef4">NCT04968574</a>).<br/><br/><strong>GKT137831 (setanaxib)</strong> inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. (<a href="https://clinicaltrials.gov/study/NCT03865927">NCT03865927</a>).<br/><br/><strong>HZN-825</strong>, a lysophosphatidic acid receptor 1 (LPAR1) antagonist. (<a href="https://clinicaltrials.gov/study/NCT05032066">NCT05032066</a>) <br/><br/><strong>Ifetroban</strong>, a potent and selective thromboxane-prostanoid receptor (TPr) antagonist, which exhibits a high affinity for TPr on platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity (<a href="https://clinicaltrials.gov/study/NCT05571059">NCT05571059</a>).<br/><br/><strong>INS018_055</strong>, a small-molecule, oral antifibrotic candidate notable for being the first entirely AI-generated drug to enter phase 2 trials. Trial enrollment started in October (<a href="https://clinicaltrials.gov/study/NCT05975983">NCT05975983</a>, <a href="https://clinicaltrials.gov/study/NCT05938920">NCT05983920</a>)<br/><br/><strong>Jaktinib dihydrochloride monohydrate</strong>, an oral JAK1, JAK2, and JAK3 inhibitor (<a href="https://clinicaltrials.gov/study/NCT04312594">NCT04312594</a>). <br/><br/><strong>Leramistat</strong>, an anti–tumor necrosis factor (TNF) agent (<a href="https://clinicaltrials.gov/study/NCT05951296">NCT05951296</a>). <br/><br/><strong>LTP001</strong>, an oral, selectively deuterated form of pirfenidone designed to retain the antifibrotic and anti-inflammatory activity of pirfenidone with a differentiated pharmacokinetic profile (<a href="https://clinicaltrials.gov/study/NCT05497284">NCT05497284</a>, <a href="https://clinicaltrials.gov/study/NCT05321420">NCT05321420</a>).<br/><br/><strong>ME-015 (suplatast tosilate)</strong> aims to stabilize ion channels in the neuronal endings in the lungs that mediate IPF-related cough (<a href="https://clinicaltrials.gov/study/NCT05983471">NCT05983471</a>). <br/><br/><strong>Nalbuphine</strong>, a small-molecule, dual-mechanism treatment for chronic cough in IPF. It acts as both a mu opioid receptor antagonist and a kappa opioid receptor agonist (<a href="https://clinicaltrials.gov/study/NCT05964335">NCT05964335</a>). The CANAL trial, complete last year, is evaluating an extended-release formulation (<a href="https://clinicaltrials.gov/study/NCT04030026">NCT04030026</a>). <br/><br/><strong>NP-120 (ifenprodil)</strong>, a small-molecule N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA-type subunit 2B (GluN2B) (<a href="https://clinicaltrials.gov/study/NCT04318704">NCT04318704</a>).<br/><br/><strong>Orvepitant</strong>, a selective antagonist for the NK₁ receptor, is being evaluated to treat IPF-related cough (<a href="https://clinicaltrials.gov/study/NCT05185089">NCT05815089</a>). <br/><br/><strong>RXC007 (zelasudil)</strong>, a Rho-associated coiled-coil–containing protein kinase 2 (ROCK2) selective inhibitor, was granted FDA orphan drug designation in August 2023 (<a href="https://clinicaltrials.gov/study/NCT05570058">NCT05570058</a>).<br/><br/><strong>Saracatinib</strong>, a selective Src kinase inhibitor originally developed for oncological indications (<a href="https://clinicaltrials.gov/study/NCT04598919?cond=Idiopathic Pulmonary Fibrosis&lastUpdPost=2021-06-01_2023-09-16&aggFilters=phase:0 1 2 3,status:act com not rec&page=9&rank=82">NCT04598919</a>). <br/><br/><strong>SHR-1906</strong>, an intravenous treatment, inhibits binding of a target protein to a variety of cytokines and growth factors, affects downstream signaling pathways, and reduces cell proliferation and migration (<a href="https://clinicaltrials.gov/study/NCT05722964?cond=Idiopathic Pulmonary Fibrosis&page=5&rank=45">NCT05722964</a>).<br/><br/><strong>TTI-101</strong>, an oral, small-molecule inhibitor of signal transducer and activator of transcription (STAT3), which has been found to accumulate in the lungs of IPF patients (<a href="https://clinicaltrials.gov/study/NCT05671835">NCT05671835</a>).<br/><br/><strong>VAY736 (lanalumab)</strong>, a BAFF-R inhibitor (<a href="https://clinicaltrials.gov/study/NCT03287414">NCT03287414</a>).<br/><br/><strong>Vixarelimab</strong>, a human monoclonal oncastatin M receptor beta antibody (<a href="https://clinicaltrials.gov/study/NCT05785624">NCT05785624</a>). <br/><br/>Some investigative programs, however, didn’t make it out of phase 2. The trial evaluating inhaled GB0139, a selective functional antagonist of G-protein–coupled receptor 84, which plays a key role in fibrosis, failed to meet its primary endpoint (<a href="https://clinicaltrials.gov/study/NCT03832946">NCT03832946</a>). Likewise, oral GLPG1205 failed to show a significant difference in FVC decline vs. placebo (<a href="https://erj.ersjournals.com/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03725852&atom=%2Ferj%2Fearly%2F2022%2F10%2F20%2F13993003.01794-2022.atom">NCT03725852</a>). The program to develop SAR156597, also known as romilkimab, was halted (<a href="https://clinicaltrials.gov/study/NCT02345070">NCT02345070</a>). ND-L02-s0201n, an siRNA oligonucleotide drug designed to inhibit heat shock protein 47 (HSP47), which regulates collagen synthesis and secretion that causes fibrosis, didn’t show the expected efficacy (<a href="https://clinicaltrials.gov/study/NCT03538301">NCT03538301</a>). <br/><br/></p> <h2>Phase 1 trials</h2> <p>No fewer than 27 phase 1 trials are evaluating investigative treatments for IPF, many in the early phase or not yet recruiting. According to GlobalData, phase 1 drugs for IPF have a 66% chance of moving onto phase 2. Among the advanced phase 1 trials that have gained corporate backing are: </p> <p><strong>9MW3811</strong>, an anti–interleukin-11 monoclonal antibody IV injection (<a href="https://clinicaltrials.gov/study/NCT05912049">NCT05912049</a>).<br/><br/><strong>ANG-3070</strong>, an oral tyrosine kinase inhibitor targeting platelet-derived growth factor (PDGFR) alpha and beta (<a href="https://clinicaltrials.gov/study/NCT05387785">NCT05387785</a>).<br/><br/><strong>C106</strong>, an angiotensin II type 2 receptor agonist (<a href="https://clinicaltrials.gov/study/NCT05427253">NCT05427253</a>).<br/><br/><strong>HuL001</strong>, which targets alpha-enolase (<a href="https://clinicaltrials.gov/study/NCT04540770">NCT04540770</a>).<br/><br/><strong>LTI-03</strong>, a Caveolin-1 (Cav1)-related peptide designed to restore Cav1 expression in lung tissue (<a href="https://clinicaltrials.gov/study/NCT05954988">NCT05954988</a>).<br/><br/><strong>ORIN1001</strong>, a first-in-class small molecule that selectively blocks the inositol requiring enzyme 1alphase (IRE1) RNAse and blocks X-box binding protein 1 (XBP1) activation (<a href="https://clinicaltrials.gov/study/NCT04643769">NCT04643769</a>). <br/><br/><strong>PRS-220</strong> is an orally inhaled anticalin protein targeting connective tissue growth factor (CTGF) (<a href="https://clinicaltrials.gov/study/NCT05473533?cond=Idiopathic Pulmonary Fibrosis&lastUpdPost=2021-06-01_2023-09-16&aggFilters=phase:0 1 2 3,status:act com not rec&page=12&rank=115">NTC05473533</a>).<br/><br/><strong>TRK-250</strong>, a single-strand, long-chain nucleic acid that selectively suppresses expression of transforming growth factor-beta 1 (TGF-beta1) protein (<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03727802">NCT03727802</a>).<br/><br/>“While we have therapies that we’re able to give patients, we need to do more and we need to do better,” Dr. Lee said. “We’re all hopeful the next phase 3 clinical trial will be something that will help change the treatment paradigm for our patients. We’re very patient, and hopefully those that are interested in improving this treatment landscape will continue to persist.”<br/><br/>Dr. Lee disclosed financial relationships with Boehringer Ingelheim, Pliant Therapeutics, Blade Therapeutics, United Therapeutics, Eleven P15. and Avalyn Pharma.<span class="end"/></p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>
